Literature DB >> 32484810

Studies of royal jelly and associated cross-reactive allergens in atopic dermatitis patients.

Taketoshi Hata1,2, Takako Furusawa-Horie1, Yasuko Arai1, Tomoko Takahashi2, Mariko Seishima2, Kenji Ichihara1.   

Abstract

Royal jelly (RJ), a creamy substance secreted by honeybees, is the exclusive diet for queen bee differentiation and life maintenance. RJ has been used in cosmetics, beverages, medicines, and supplements worldwide. However, allergy is a concerning issue for RJ, especially in atopic dermatitis (AD) and asthma patients. In some cases, allergic reactions are seen after the first intake of RJ, suggesting the existence of allergens cross-reactive with RJ. Information about the cross-reactive allergens is very important for the safe application of RJ; however, study of this cross-reactivity is quite limited. In this study, we attempted to identify allergens cross-reactive with RJ by using serum samples from 30 AD patients who had never been exposed to RJ. In an enzyme-linked immunosorbent assay (ELISA) experiment, RJ-binding IgE antibodies were detected in the serum of 10 out of 30 patients, and their antibody titers ranged from 4- to 2,048-fold dilution ratios. Additionally, 3 AD patients were determined to be positive in a skin-prick test (SPT) with an RJ solution. Significant correlations were observed between the anti-RJ antibody titer and nonspecific IgE and between the anti-RJ antibody titer and the Eczema Area and Severity Index score. We further examined the cross-reactivity between RJ and 14 typical allergens by using an ELISA-inhibition assay and demonstrated that the following 6 allergens showed cross-reactivity with RJ: the European house dust mite (HDM) (Dermatophagoides pteronyssinus), American HDM (Dermatophagoides farinae), snow crab (Chionocetes spp.), edible crab (Cancer pagurus), German cockroach (Blatella germanica), and honeybee venom (Apis mellifera). In conclusion, people with a history of allergic diseases, including AD, asthma, and allergic rhinitis, should be cautioned against consuming RJ products because of the potential for cross-reactive responses to ensure the safe and successful use of RJ supplements.

Entities:  

Year:  2020        PMID: 32484810     DOI: 10.1371/journal.pone.0233707

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  5 in total

1.  Classification of patients with esophageal eosinophilia by patterns of sensitization revealed by a diagnostic assay for multiple allergen-specific IgEs.

Authors:  Akinobu Nakata; Fumio Tanaka; Yuji Nadatani; Shusei Fukunaga; Koji Otani; Shuhei Hosomi; Noriko Kamata; Koichi Taira; Yasuaki Nagami; Toshio Watanabe; Yasuhiro Fujiwara
Journal:  J Gastroenterol       Date:  2021-02-16       Impact factor: 7.527

2.  A Case of Anaphylaxis Caused by Major Royal Jelly Protein 3 of Royal Jelly and Its Cross-Reactivity with Honeycomb.

Authors:  Jun-Da Li; Le Cui; Ying-Yang Xu; Kai Guan
Journal:  J Asthma Allergy       Date:  2021-12-22

Review 3.  General Nutritional Profile of Bee Products and Their Potential Antiviral Properties against Mammalian Viruses.

Authors:  Syeda Tasmia Asma; Otilia Bobiş; Victoriţa Bonta; Ulas Acaroz; Syed Rizwan Ali Shah; Fatih Ramazan Istanbullugil; Damla Arslan-Acaroz
Journal:  Nutrients       Date:  2022-08-30       Impact factor: 6.706

4.  Mining the Royal Jelly Proteins: Combinatorial Hexapeptide Ligand Library Significantly Improves the MS-Based Proteomic Identification in Complex Biological Samples.

Authors:  Eliza Matuszewska; Joanna Matysiak; Grzegorz Rosiński; Elżbieta Kędzia; Weronika Ząbek; Jarosław Zawadziński; Jan Matysiak
Journal:  Molecules       Date:  2021-05-07       Impact factor: 4.411

Review 5.  Honey Bee Products: Preclinical and Clinical Studies of Their Anti-inflammatory and Immunomodulatory Properties.

Authors:  Hesham R El-Seedi; Nehal Eid; Aida A Abd El-Wahed; Mostafa E Rateb; Hanan S Afifi; Ahmed F Algethami; Chao Zhao; Yahya Al Naggar; Sultan M Alsharif; Haroon Elrasheid Tahir; Baojun Xu; Kai Wang; Shaden A M Khalifa
Journal:  Front Nutr       Date:  2022-01-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.